In a 60‑year‑old man, eight months after kidney transplantation, currently receiving cyclosporine and valganciclovir, who now has diffuse bilateral interstitial opacities on chest CT, what is the recommended diagnostic work‑up and initial management?

Diagnostic Work-Up and Initial Management

In this 60-year-old kidney transplant recipient 8 months post-transplant on cyclosporine and valganciclovir presenting with diffuse bilateral interstitial opacities, you must immediately pursue CMV pneumonitis as the primary diagnosis while simultaneously evaluating for other opportunistic infections and drug-induced lung injury.

Immediate Diagnostic Work-Up

Priority Testing for CMV Disease

• Obtain quantitative CMV viral load (PCR) from plasma immediately 1
• Perform bronchoscopy with bronchoalveolar lavage (BAL) to obtain:
  • CMV quantitative PCR from BAL fluid (typically shows high viral loads in CMV pneumonitis) 2, 3
  • Bacterial, fungal, and mycobacterial cultures
  • Pneumocystis jirovecii PCR or direct fluorescent antibody
  • Cytology with rapid on-site evaluation (ROSE) to exclude fungal infections (particularly Mucorales given immunosuppression) 4
  • Consider metagenomic next-generation sequencing (mNGS) if initial studies are negative 5

Critical Context

The patient is already on valganciclovir prophylaxis, which should have prevented CMV disease if taken appropriately. Breakthrough CMV disease while on prophylaxis suggests either:

• Non-adherence to medication
• Inadequate dosing (especially if renal function has declined)
• Drug-resistant CMV (consider if viremia detected despite therapy) 6
• Alternative diagnosis

Additional Essential Testing

• BK polyomavirus quantitative plasma PCR (can cause interstitial pneumonitis in transplant recipients) 1
• Serum creatinine and eGFR to assess current renal function (affects valganciclovir dosing and cyclosporine toxicity)
• Cyclosporine trough level (calcineurin inhibitors, particularly tacrolimus but also cyclosporine, can cause drug-induced interstitial lung disease) 5
• Complete blood count (valganciclovir causes myelosuppression; leukopenia/neutropenia increases infection risk)
• Serum galactomannan and beta-D-glucan for invasive fungal disease
• Blood cultures

Initial Management Algorithm

If CMV Viremia/Pneumonitis is Confirmed

1. Escalate Antiviral Therapy

• Switch from valganciclovir to IV ganciclovir 5 mg/kg twice daily (adjusted for renal function) 1
  • KDIGO guidelines specifically recommend IV ganciclovir for serious/tissue-invasive CMV disease 1
  • Continue until CMV is no longer detectable by plasma PCR or pp65 antigenemia 1
  • Monitor CMV viral load weekly 1

2. Reduce Immunosuppression

• Decrease cyclosporine dose by 25-50% 1
  • KDIGO recommends reducing immunosuppression in life-threatening CMV disease and disease persisting despite treatment 1
  • Monitor graft function closely during reduction 1
  • Check cyclosporine levels frequently to maintain lower therapeutic range

3. Monitor for Treatment Response

• Weekly CMV viral loads until undetectable
• Repeat chest imaging at 1-2 weeks
• Daily assessment of respiratory status and oxygen requirements

If CMV is Negative or Minimal

Consider Cyclosporine-Induced Interstitial Lung Disease

• Although more commonly reported with tacrolimus, cyclosporine can cause drug-induced pneumonitis 5
• Management approach:
  • Switch cyclosporine to alternative immunosuppression (e.g., mycophenolate mofetil or azathioprine) 5
  • Increase corticosteroid dose (e.g., methylprednisolone 1-2 mg/kg/day) 5, 2
  • Expect improvement within 2-4 weeks if drug-induced 5
  • Never re-challenge with the offending calcineurin inhibitor 5

If Organizing Pneumonia Pattern Emerges

• Central peri-bronchovascular distribution with peripheral sparing suggests organizing pneumonia (can occur post-CMV infection) 2
• Requires high-dose corticosteroids (e.g., methylprednisolone 1 mg/kg/day) with gradual taper 2
• Expect dramatic response within days to weeks 2

Critical Pitfalls to Avoid

1. Do not continue oral valganciclovir for suspected CMV pneumonitis - tissue-invasive disease requires IV ganciclovir 1

2. Do not delay bronchoscopy - BAL is essential to differentiate CMV pneumonitis from other opportunistic infections (PCP, fungal) and to guide targeted therapy

3. Do not maintain full immunosuppression - failure to reduce cyclosporine in severe CMV disease is associated with treatment failure and mortality 1

4. Monitor for ganciclovir-resistant CMV - if clinical deterioration occurs despite appropriate therapy and persistent viremia, consider resistance testing and switch to foscarnet 6

5. Remember the "late" post-transplant period - at 8 months, this patient is beyond typical early CMV prophylaxis but still at risk, especially if there was recent rejection treatment or increased immunosuppression 6, 7

6. Consider multiple simultaneous infections - immunosuppressed transplant recipients can have polymicrobial infections; one positive test does not exclude additional pathogens 8, 4